◉ Pipelines

Currently, Pharmasaga has two Pdia4 inhibitors, PS-001 and PS-002, for type 2 diabetes (T2D) and type 1 diabetes (T1D), respectively. Their pre-clinical studies were completed in 2021.

US FDA approved the application of investigation drug (IND), PS-001. We are scheduled to start phase 1 clinical trial of PS-001 by the third quarter of 2022 and complete it by the end of 2022.  Its phase 2 clinical trial is scheduled to start in 2023 and complete it by the end of 2025.

Pharmasaga will also launch the same small molecule (re-named as PS-002) for the treatment of T1D in 2022 to increase our product pipeline.